Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This Study Evaluates the Addition of Dapagliflozin in the Treatment of Type 2 Diates With Metformin and JT-003 Combination Therapy.

NCT05296044 is registered in ClinicalTrials.gov with Jeil Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05296044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05296044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This Study Evaluates the Addition of Dapagliflozin in the Treatment of Type 2 Diates With Metformin and JT-003 Combination Therapy.
Lead sponsor
Jeil Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
April 5, 2022
Completion date
February 28, 2024
Enrollment
245 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus